Stocks
Atea Projects Over $700M Annual U.S. HCV Revenue Potential
Atea Pharmaceuticals (AVIR) outlined peak annual U.S. net revenue potential exceeding $700 million, driven by its mid-2028 hepatitis C (HCV) launch. This...
Atea Pharmaceuticals (AVIR) outlined peak annual U.S. net revenue potential exceeding $700 million, driven by its mid-2028 hepatitis C (HCV) launch. This...